Waterland — backed Cruinn Diagnostics buys UK’s Katalyst Diagnostics

Cruinn Diagnostics agreed to acquire UK point-of-care diagnostics provider Katalyst Diagnostics to enter the UK market. Deal adds NHS customer relationships, UK commercial infrastructure, and a complementary point-of-care portfolio alongside Cruinn’s laboratory diagnostics business. Combined group exceeds 100 employees with revenue above EUR 50 million. Katalyst will keep its existing leadership, with Afsheen Khan continuing as managing director. Cruinn targets revenue of EUR 150 million over coming years through organic growth and further UK-Ireland acquisitions. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Waterland Private Equity Investments BV published the original content used to generate this news brief on September 24, 2026, and is solely responsible for the information contained therein. (C)